

REMARKS

We appreciate the Examiner pointing out the errors in claims 1, 16 and 27. We have amended the claims to correct the errors, with support for the amendments being found in column 3, lines 14-16 and column 14, lines 16-18 (claim 1 and 16 amendments), as well as in column 2, line 48 and column 6, line 10 (claim 27 amendment). In light of these amendments, withdrawal of the Section 112, second paragraph rejection of the claims 1-32 is respectfully requested.

To overcome the obviousness-type double patenting rejection of claims 16-31 over claims 1-15 of U.S. Patent No. 5,631,394, we submit herewith a terminal disclaimer that complies with 37 C.F.R. §1.321(c).

In light of the foregoing, we respectfully submit that the claims, as amended, define a novel and non-obvious invention which fully merits patent protection. We therefore respectfully request that the entire application be allowed at an early date.

No fee is deemed necessary in connection with the filing of this Amendment, as it is being filed within three months of the mailing date of the outstanding Office Action. However, if any fee is required, authorization is hereby given to charge the amount of such a fee to Deposit Account No. 12-1635.

July 25, 2000
Date

144cRISamd1.DOC

Respectfully submitted,



Russell G. Lindenfeldar
Attorney for Applicants
Registration No. 39,750
THE LIPOSOME COMPANY, INC.
One Research Way
Princeton Forrestal Center
Princeton, NJ 08540
(609) 452-7060